Tyrosine kinase inhibitor (VEGFR): Class Overview and Comparison
Quick answer: Tyrosine kinase inhibitor (VEGFR) are a class of medicines used for specific therapeutic indications. iMedic covers 3 tyrosine kinase inhibitor (vegfr) substances. Below is a comparison table linking to detailed pages for each.
Tyrosine kinase inhibitor (VEGFR) on iMedic (3 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Axitinib | Advanced renal cell carcinoma | Selective inhibitor of VEGFR-1, -2, and -3 tyrosine kinases, blocking tumor angi | 5 mg twice daily, titrated up to 10 mg twice daily |
| Fotivda | Advanced renal cell carcinoma | Tivozanib selectively inhibits VEGFR-1, -2, and -3 tyrosine kinases to block tum | 1.34 mg orally once daily for 21 days, then 7 days off (28-day cycle) |
| Fruzaqla | Previously treated metastatic colorectal cancer | Fruquintinib is a highly selective oral inhibitor of VEGFR-1, -2, and -3 that su | 5 mg orally once daily for 21 days of each 28-day cycle |
About Tyrosine kinase inhibitor (VEGFR)
Tyrosine kinase inhibitor (VEGFR) share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Tyrosine kinase inhibitor (VEGFR)?
Tyrosine kinase inhibitor (VEGFR) are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 3 substances in this class with detailed pages for each.
Are all Tyrosine kinase inhibitor (VEGFR) interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Tyrosine kinase inhibitor (VEGFR)?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Tyrosine kinase inhibitor (VEGFR) available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.